IP Library Granted Patent US 8,609,645
Granted Patent B2
US 8,609,645 · App. 13/293,994 · Granted Dec 17, 2013

Pharmaceutical formulation

Inventors: Abu S. Huq (Plainsboro, NJ); Allan J. Weingarten (Summit, NJ); Robert D. Simmons (Summit, NJ)
Assignee: Intervet Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,609,645
App. No.
13/293,994
Granted
Dec 17, 2013
Kind
B2
Abstract

Disclosed are novel formulations for the treatment of otic infections in an animal comprising a triazole anti-fungal compound, a quinolone antibiotic and a corticosteroid such as mometasone furoate monohydrate.

Claims (4)

1. A pharmaceutical composition for the treatment of an otic infection in an animal comprising Orbifloxacin or one of its pharmaceutically acceptable salts in an amount of about 0.1% to about 10% by weight, Posaconazole in an amount of about 0.01% to about 1% by weight, Mometasone in an amount of about 0.01% to about 1% by weight, a viscocity enhancing agent in an amount of about 0.1% to about 5% by weight, and at least one pharmaceutically acceptable carrier, wherein said composition is a suspension.

2. The composition according to claim 1 , wherein the viscosity enhancing agent is selected from the group consisting of methylcellulose, water soluble salts of cellulose ethers, carboxymethyl hydroxyethyl cellulose, hydroxyethyl cellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, sodium alginate, carbomer, providone, acacia, guar gum, xanthan gum, gum karaya, gum arabic, gum tragacanth, magnesium aluminum silicate, carboxyvinyl polymers, carrageenen, laponite, and mineral oil with polyethylene.

3. The composition according to claim 1 , wherein about 1% of the composition is Orbifloxacin.

4. The composition according to claim 1 , wherein about 0.1 wt % of the composition is Posaconazole.

Assignments (1)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
Continuity (3)
Division 11201044 · Aug 10, 2005
Provisional Application 60601475 · Aug 13, 2004
Related Publication 20120058964A1 · Mar 8, 2012